Internal Medicine, Hematology & Oncology · Beaumont, TX
NPI
1699713198
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
3070 College St, Suite 301
Beaumont, TX, 77701
Phone (409) 813-1686
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.8M
137,812 services
Medicare patients, 2024
596
Average age 75
Drug cost, 2024
$2.1M
1,267 prescriptions
Company payments, 2025
$755
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sumalatha Patibandla was code J1756 (injection, iron sucrose, 1 mg), 21,600 times for 50 patients. In total Sumalatha Patibandla billed 137,812 services in 158 codes, and Medicare paid $1.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-04-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1756 Injection, iron sucrose, 1 mg | Office | 21,600 | 50 | $0.18 | $3,830 |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 21,420 | 28 | $0.28 | $5,909 |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 10,635 | 27 | $2.31 | $25K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 7,941 | 73 | $0.10 | $823 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 7,600 | 18 | $44.58 | $339K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 3,150 | 12 | $0.11 | $359 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,431 | 74 | $0.09 | $126 |
| 85025 Blood Count | Office | 1,226 | 318 | $7.58 | $9,298 |
| 80053 Clinical Chemistry | Office | 1,176 | 332 | $10.34 | $12K |
| 36415 Venipuncture Blood Collection | Office | 916 | 253 | $8.63 | $7,907 |
| 99214 Office E&M - Established | Office | 814 | 271 | $87.32 | $71K |
| 83735 Clinical Chemistry | Office | 561 | 58 | $6.57 | $3,686 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 523 | 257 | $12.10 | $6,328 |
| 83615 Clinical Chemistry | Office | 505 | 289 | $5.90 | $2,979 |
| 83540 Clinical Chemistry | Office | 432 | 239 | $6.30 | $2,723 |
By year: 2022 $1.7M for 110,555 services; 2023 $1.4M for 105,575 services; 2024 $1.8M for 137,812 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 1,226 | 318 | $7.58 | $9,298 |
| 80053 Clinical Chemistry | 1,176 | 332 | $10.34 | $12K |
| 36415 Venipuncture Blood Collection | 916 | 253 | $8.63 | $7,907 |
| 83735 Clinical Chemistry | 561 | 58 | $6.57 | $3,686 |
| 83615 Clinical Chemistry | 505 | 289 | $5.90 | $2,979 |
| 83550 Clinical Chemistry | 432 | 239 | $8.52 | $3,681 |
| 83540 Clinical Chemistry | 432 | 239 | $6.30 | $2,723 |
| 82728 Clinical Chemistry | 422 | 239 | $13.28 | $5,605 |
| 85055 Blood Count | 117 | 46 | $35.03 | $4,099 |
| 85027 Blood Count | 97 | 40 | $6.34 | $615 |
Medicare prescription drug claims, 2024
In 2024, the drug Sumalatha Patibandla prescribed most often to Medicare patients was Anastrozole, with 192 prescriptions and refills. In total Sumalatha Patibandla wrote 1,267 Medicare prescriptions that cost $2.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 192 | 456 | 50 | $3,364 |
| Potassium Chloride Generic | 110 | 110 | 65 | $202 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 62 | 62 | 14 | $2,132 |
| Hydroxyurea Generic | 49 | 122 | 13 | $1,084 |
| Valacyclovir Valacyclovir Hcl | 48 | 82 | 13 | $1,509 |
| Eliquis Apixaban | 47 | 63 | Under 11 | $35K |
| Levofloxacin Generic | 46 | 46 | 17 | $223 |
| Azithromycin Generic | 40 | 40 | 32 | $148 |
| Ondansetron Hcl Generic | 38 | 38 | 16 | $350 |
| Gabapentin Generic | 29 | 52 | Under 11 | $476 |
| Fluconazole Generic | 27 | 27 | Under 11 | $820 |
| Folic Acid Generic | 26 | 66 | 11 | $122 |
| Lenalidomide Generic | 26 | 26 | Under 11 | $416K |
| Tramadol Hcl Generic | 26 | 26 | 15 | $130 |
| Letrozole Generic | 23 | 55 | Under 11 | $435 |
Brand drugs: 147 claims; generic drugs: 1,120 claims; opioid claims: 98.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sumalatha Patibandla $755 ($755 in general payments such as food, travel and fees) from 17 companies. The largest payer was Novartis Pharmaceuticals Corporation with $163.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 7 | $163 |
| Pfizer Inc. PFE | 8 | $144 |
| Deciphera Pharmaceuticals Inc. | 3 | $75.27 |
| Celgene Corporation BMY | 2 | $49.1 |
| Gilead Sciences, Inc. GILD | 2 | $46 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $38.06 |
| PharmaEssentia USA Corporation 6446.TW | 2 | $35.33 |
| Tempus AI, Inc TEM | 1 | $29.56 |
| GlaxoSmithKline, LLC. GSK | 1 | $28.19 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $23.56 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.